AnaptysBio Inc logo

ANAB - AnaptysBio Inc News Story

$26.16 0.6  2.2%

Last Trade - 07/05/21

Sector
Healthcare
Size
Mid Cap
Market Cap £512.4m
Enterprise Value £240.2m
Revenue £51.0m
Position in Universe 3192nd / 6858

AnaptysBio Announces Appointment of Oleg Nodelman to Board of Directors

Mon 12th April, 2021 9:00pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210412:nGNX8kn3x0&default-theme=true


SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB),
a clinical-stage biotechnology company developing first-in-class antibody
product candidates focused on emerging immune control mechanisms applicable to
inflammation and immuno-oncology indications, today announced the appointment
of Oleg Nodelman to the company’s Board of Directors.   

“Oleg is an experienced biotechnology company builder with deep insight in
the development and financing of novel therapies,” said Hamza Suria,
president and chief executive officer of AnaptysBio. “We welcome Oleg to
our Board of Directors and look forward to his contributions to AnaptysBio’s
capital-efficient antibody discovery and development business model.”

“AnaptysBio has an impressive antibody development heritage that has led to
the advancement of eight internally-generated novel therapeutics into clinical
development,” commented Mr. Nodelman. “I look forward to working with the
company’s Board and management team to advance AnaptysBio’s first-in-class
wholly-owned antibody pipeline for inflammatory and immuno-oncology
applications.”

About AnaptysBio
AnaptysBio is a clinical-stage biotechnology company developing
first-in-class antibody product candidates focused on emerging immune control
mechanisms applicable to inflammation and immuno-oncology indications. The
Company’s proprietary anti-inflammatory pipeline includes its anti-IL-36R
antibody imsidolimab, previously referred to as ANB019, for the treatment of
rare inflammatory diseases, including generalized pustular psoriasis, or GPP,
EGFRi skin toxicity, ichthyosis, hidradenitis suppurativa and acne; its
anti-PD-1 agonist program, ANB030, for treatment of certain autoimmune
diseases where immune checkpoint receptors are insufficiently activated; and
its BTLA modulator program, ANB032, which is broadly applicable to human
inflammatory diseases associated with lymphoid and myeloid immune cell
dysregulation. AnaptysBio’s antibody pipeline has been developed using its
proprietary somatic hypermutation, or SHM platform, which uses in vitro SHM
for antibody discovery and is designed to replicate key features of the human
immune system to overcome the limitations of competing antibody discovery
technologies. AnaptysBio has also developed multiple therapeutic antibodies
in an immuno-oncology collaboration with GlaxoSmithKline, including an
anti-PD-1 antagonist antibody (dostarlimab GSK4057190A), an anti-TIM-3
antagonist antibody (cobolimab, GSK4069889A) and an anti-LAG-3 antagonist
antibody (GSK4074386), and an inflammation collaboration with Bristol-Myers
Squibb, including an anti-PD-1 checkpoint agonist antibody (CC-90006)
currently in clinical development.

Contacts:
Dennis Mulroy
AnaptysBio, Inc.
858.732.0201
dmulroy@anaptysbio.com



(https://www.globenewswire.com/NewsRoom/AttachmentNg/04e9e812-bf31-4349-997d-639cc0f17ebf)



GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.